China Pharmaceutical Logistics Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | Biologics Fuel Cold-Chain and Value-Added Services Opportunities

Boost ROI through PREMIUM cold-chain corridors, value-added compliance services, digital integration, route density, and scalable national distribution networks.

Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "China Pharmaceutical Logistics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.

The China pharmaceutical logistics market size is projected to increase from USD 57.34 billion in 2025 to USD 60.29 billion in 2026, reaching USD 76.61 billion by 2031. The market is forecast to grow at a CAGR of 4.91% from 2026 to 2031, supported by an aging population, sustained demand for medicines, extensive domestic pharmaceutical production, and regulations that increasingly Connect Group distribution quality with drug safety and service consistency.

Expansion of the National Essential-Drug Distribution Network

The updated 2025 National Basic Medical Insurance Drug Directory expanded the reimbursed product base and introduced a commercial health insurance category for innovative drugs. Wider reimbursement is expected to increase the volume of medicines moving through licensed hospital, pharmacy, and distribution channels.

This expansion is creating demand for additional ambient storage and qualified Cold-Chain infrastructure as innovative therapies become available to more patients. Policy priorities under the 15th Five-Year Plan also favor larger national distribution networks with stronger compliance systems, denser transportation routes, and more efficient procurement capabilities.

As the national medicine distribution network develops, logistics providers must meet higher standards for traceability, serialization, temperature monitoring, and delivery consistency. Operators unable to invest in compliant facilities, digital systems, and temperature-controlled assets may face increasing pressure as regulatory expectations rise.

Biologics Drive Temperature-Controlled Logistics Demand

Rapid growth in biologics and other temperature-sensitive pharmaceutical products is reshaping the China pharmaceutical logistics market. Pharmaceutical Cold-Chain logistics costs reached CNY 26.78 billion, equivalent to approximately USD 3.79 billion, in 2025. Cold storage capacity increased by 5.43% to 4.525 million cubic meters, outpacing growth in ambient warehousing.

Cell and gene therapies are adding further complexity to pharmaceutical transportation. While many products require temperatures between 2 C and 8 C, certain therapies must be maintained under cryogenic conditions ranging from -150 C to -196 C. These requirements increase demand for specialized equipment, validated handling procedures, trained personnel, real-time monitoring, and effective exception management.

Qualified Cold-Chain providers can command higher pricing for specialized services than operators focused on standard ambient distribution. As a result, investment is moving toward PREMIUM Cold-Chain corridors, validated storage facilities, and technology-enabled monitoring systems, even as procurement-related price pressure continues across conventional medicine distribution.

Rural Last-Mile Infrastructure Remains a Key Constraint

Rural last-mile capacity continues to limit pharmaceutical distribution efficiency. China's pharmaceutical vehicle fleet reached 46,416 units in 2025, but investment remained concentrated in major urban corridors. Lower-tier markets, particularly in western and mountainous provinces, often have fewer certified vehicles, limited route redundancy, and longer replenishment times.

Road-only delivery can also conflict with temperature stability requirements for time-sensitive medicines. Regional socio-economic differences continue to affect access to essential drugs, while providers supporting centralized procurement contracts may encounter last-mile expenses that are not fully reflected in contract pricing. This can restrict funding for fleet modernization, certified storage, and service expansion.

Drone delivery pilots in Hainan, Yunnan, Xinjiang, and Chongqing demonstrate the potential of alternative transportation models. However, commercial coverage remains limited across many difficult inland routes.

Transportation Leads While Value-Added Services Accelerate

Transportation accounted for 52.46% of the China pharmaceutical logistics market in 2025. Road freight remained the primary mode for intercity transfers, hospital deliveries, pharmacy restocking, and urban replenishment. Air freight supported urgent biologics, clinical materials, and high-value shipments, while sea and inland waterways served selected bulk ambient routes.

National pharmaceutical warehousing capacity reached 93.816 million cubic meters in 2025, providing a substantial storage base for the transportation network. However, Value-Added services are forecast to grow at a CAGR of 7.74% through 2031 as pharmaceutical manufacturers increasingly outsource serialization, GDP-compliant temperature monitoring, DTP pharmacy fulfillment, and Cold-Chain-as-a-service capabilities.

Additional market growth will be influenced by the rise of E-Commerce pharmacies and 24-Hr delivery expectations, stricter GDP audit and licensing enforcement, and escalating Cold-Chain energy costs under carbon caps. Future competitiveness will depend on digital integration, regulatory compliance, validated handling, network reach, and reliable temperature-controlled delivery across both urban and rural China.

Key Topics Covered:

1 Introduction
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape
4.1 Market Overview and Role of Logistics in Pharmaceutical
4.2 Pharmaceutical Spending Trends
4.3 Market Drivers
4.3.1 Expansion of the National Essential-Drug Distribution Network
4.3.2 Rapid Growth in Biologics and Temperature-Controlled Demand
4.3.3 Rise of E-Commerce Pharmacies and 24-Hr Delivery Expectations
4.3.4 Stricter GDP Audit and Licensing Enforcement
4.3.5 Centralized-Procurement Hubs Drive Regional Consolidation
4.3.6 Pilots of Drones/AVs for Western-Province Mid-Mile Routes
4.4 Market Restraints
4.4.1 Fragmented Rural Last-Mile Infrastructure
4.4.2 Escalating Cold-Chain Energy Costs Under Carbon Caps
4.4.3 Dry-Ice Supply Rules for MRNA Vaccines
4.4.4 Urban Hospital Traffic-Control Delivery Curfews
4.5 Regulatory Framework
4.6 Value Chain and Distribution Channel Architecture Analysis
4.7 Technology Innovations Outlook
4.8 Porter's Five Forces Analysis
4.8.1 Threat of New Entrants
4.8.2 Bargaining Power of Suppliers
4.8.3 Bargaining Power of Buyers
4.8.4 Threat of Substitutes
4.8.5 Rivalry Among Competitors
4.9 Evolution of Pharmaceutical Logistics Requirements
4.10 Impact of Geo-Political Events on Supply Chain Shifts

5 Market Size and Growth Forecasts
5.1 By Logistics Function
5.1.1 Transportation
5.1.1.1 Road
5.1.1.2 Air
5.1.1.3 Sea and Inland Waterways
5.1.1.4 Rail
5.1.2 Warehousing and Distribution
5.1.3 Value-added Services and Others
5.2 By Mode of Operation
5.2.1 Cold-Chain Logistics
5.2.2 Non-Cold-Chain Logistics
5.3 By Product Type
5.3.1 Prescription Drugs
5.3.2 OTC Drugs
5.3.3 Biologics and Biosimilars
5.3.4 Vaccines and Blood Products
5.3.5 Clinical Trail Materials
5.3.6 Cell and Gene Therapies
5.3.7 Medical Devices and Diagnostics
5.3.8 Veterinary Medicine
5.3.9 Others
5.4 By Region
5.4.1 North
5.4.2 Northeast
5.4.3 East
5.4.4 Central
5.4.5 South
5.4.6 Southwest
5.4.7 Northwest

6 Competitive Landscape
6.1 Market Concentration
6.2 Key Strategic Moves
6.3 Market Share Analysis
6.4 Company Profiles (Includes Global Level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products and Services, and Recent Developments)
6.4.1 Sinopharm Logistics
6.4.2 SF Express
6.4.3 JD Logistics
6.4.4 DHL Group
6.4.5 United Parcel Service of America, Inc. (UPS)
6.4.6 Kuehne+Nagel
6.4.7 DSV A/S (Including DB Schenker)
6.4.8 FedEx
6.4.9 Cencora
6.4.10 CJ Rokin Logistics
6.4.11 Nippon Express Holdings
6.4.12 Yamato Holdings
6.4.13 ZTO Express
6.4.14 YTO Express
6.4.15 STO Express
6.4.16 China Post EMS
6.4.17 Cainiao Smart Logistics Network
6.4.18 CMA CGM Group (Including CEVA Logistics)
6.4.19 DCH Auriga
6.4.20 Sinotrans Limited
6.4.21 China Resources Pharmaceutical Commercial
6.4.22 Jointown Pharmaceutical Group

7 Market Opportunities and Future Outlook
7.1 White-space and Unmet-Need Assessment

For more information about this report visit https://www.researchandmarkets.com/r/ef40xz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900